Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679342 | 0.79 | TLR4 (0.51) | CHEK1MAPT | |
| SCHEMBL4961130 | 0.79 | CHEK1 (0.50) | CHEK1KMT2APARP1AURKAMEN1 | |
| SCHEMBL7046933 | 0.78 | KIF11 (0.39) | KIF11CHEK1KMT2APARP1AURKA | |
| Benzene SCHEMBL28184721 | 0.77 | KIF11 (0.81) | KIF11KMT2AMEN1MAPTTTK | |
| SCHEMBL6299735 | 0.77 | KIF11 (0.81) | KIF11KMT2AMEN1MAPT | |
| SCHEMBL675117 | 0.77 | KIF11 (0.51) | KIF11CHEK1AURKAMAPTALK | |
| SCHEMBL29823607 | 0.76 | KIF11 (1.00) | KIF11KMT2APARP1MEN1MAPT | |
| SCHEMBL2775335 | 0.76 | KIF11 (1.00) | KIF11KMT2APARP1MEN1MAPT | |
| SCHEMBL676054 | 0.76 | AURKA (0.49) | KIF11AURKAALK | |
| SCHEMBL4428308 | 0.76 | KIF11 (0.50) | KIF11KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| WO-2010025872-A2 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2010-03-11 | — | — | WO | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
| EP-1896472-A1 | ALPHA-CARBOLINES AS CDK-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006131552-A1 | ALPHA-CARBOLINES AS CDK-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-14 | — | — | WO | disclosed |
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | SUGEN, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6514981-B1 | By contacting cells expressing said protein tyrosine kinase with compound | SUGEN, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | KIF11 2832/4885CHEK1 1744/4885KMT2A 492/4885 |
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | LCK, ABL1, PNCK | KIF11 3404/4885CHEK1 598/4885KMT2A 1912/4885 |
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | CDKL1, CDK1, CCNA1 | KIF11 1023/4885CHEK1 75/4885KMT2A 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.